Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Your simply trying to shake weak hands...good luck with that.
That's just wrong, .40 warrants less fees, you really think they are not going to exercise their .40 warrants really?.
Don't need a secondary, already have warrants in place between .40/ $1.50 [the .40 may be exercised very soon next few weeks raising approx. 2.9 million less costs] or Tapimmune can exercise at .70.
Total cash that may be raised in the $34 million $1.50 or less over next 5 years.
While it is dilution, it allows them to licence all of the technology's from Mayo, enter Phase 11 on multiple indications, pays all fees in regards to FDA for Phase 11 and have enough cash that they meet requirements for Nasdaq listing.
Hope that helps.
Blu
Eagle1, 123tom and others thanks for your comments, I know that we are all getting excited and with good reason, but just remember that these price levels are just the beginning the stock is a steal any where under $1 or two as they enter Phase 11 within 6 months [latest].
This is the first correlation between Mayo and Tapimmune of any real consequence that I have observed; no one was making the connection that has all changed now with Edith Perez interview. This has the potential to be monstrous, one of the most viable stocks that I have seen in many years.
Look at the valuations of others in the space, but more importantly as I have reiterated before, I bought the stock because of the tremendous work that Wilfred Jefferies of UBC did to discover TAP technology. Everything has morphed from that platform, Edith Perez {Herceptin] Roche anyone else making the correlation for what may be waiting down the road.
As I have stated I believe that Tapimmune and its selectively picked advisors are looking for an acquisition or buyout, it is a very real possibility Roche most definitely; if I was the CEO of Roche TPIV would have my attention.
All warrants exercised let’s say top end 80 to 100 million, at $5, ½ billion cheap by any standard, if they have what is being bandied about, $10 makes it 1 billion also not out of the question by any means, as two other companies last year had billion dollar valuations.
Just remember this is just the tip don’t be too quick to cash in your double, we will wait quite awhile until we come across another with this potential, I personally will not be risking the massive breakout that is most likely to occur now that the correlation has been made.
I’m a fundamental guy, so this is the perfect stock; don’t think charting will be of much use in this one as cancer and this space are all the rage. To GLTA each has their own agenda, just saying the upcoming catalyst‘s far out way whatever short term consolidation may occur.
If they have it, look at other valuations in the space $10 to $70.
GLTA BLU
034runner: Acquisition is a very, very big factor almost everyone involved with Tapimmune has gone that route, they have not assembled this team without a game plan.
There is not one Big Pharma out there that cannot utilize their technology, now that have licenced the her2/neu and are working on the triple negative people are beginning to make the correlation between the two.
Stock has been consolidating as it has moved up, I believe that selling has been one of our investors shaving their position, to exercise their .40 warrants.
Remember you all have just come to the party, but TPIV is very undervalued at these prices, don't worry about the crumbs here at .40, .60 or even .75 as there is a hero sandwich in the oven.
Up...consolidate, UP...consolidate, perfect storm!
Yes she was the principle on the Herceptin study, so who better to know if our vaccine is better or not. The major hurdle we have had to overcome in the past is investors not making the correlation between Tapimmune and the Mayo clinic after ASCO this correlation should be cleared up.
So far the Mayo, at least to all my DD, has made very few comments tying TPIV in their trials.
We have now acquired/completed one licence deal, and are working on closing second, with any luck now the investing community at large will make that correlation.
Blu
Who cares about Bio Meds...the technology speaks for itself what are you missing.
All peer reviewed articles since 1993, great patent protection, almost 100 mill in tax credits down the road, some of the greatest Immunologists in the world involved.
Proven technology to date.
Great post: Like I mentioned, this may be one in a thousand stocks any of us have ever been fortunate enough to be well ahead of major catalyst's. Don't short yourself with only a double, once again have been in for longer than most.
Management has done an awesome job of implementing each and every step to date, it was just a matter of time till validation occurred.
It seems we are on the cusp, like I mentioned last week, watch the video of Edith, she is truly excited, yet held no promise of a vaccine even two years ago.
Remember "multiple" multi billion dollar indications, and upon Nasdaq listing our baby will graduate, with the likes of KITE, JUNO, IMMUNOGEN and others.
Now are you starting to believe in the buyout scenario?
After entering Phase 11 in at least two indications, Big Pharma may be courting us sooner than later.
Blu
Completely understand...just saying be very careful of that .40/.45 resistance some are talking about. Have been here for years and the investor community at large seems to nave been waiting for this data, most investors may finally realize that our valuation is "ridiculous"
Funding, Phase 11 trial commencement, low float, institutional participation, and great clinical scientist's, potential grant funding, and partial Phase 11 funding by Mayo in place, what more will the market need to fully embrace the stock.
Blu
Just a note...those of you showing views of charts. Charts are of limited use in the market, as the market has very little rational, the true measure of a public trading company are the fundamentals.
On any given day there are a million different scenarios that can change what seems to be built into a chart, and there will be little if not any warning to those events.
Tap immune in the near future [6 months] has many catalysts which the market and those charts will not be able to predict, points in fact.
1. Market as a whole is just beginning to digest the Phase 1 data, and TPIV is just beginning to gain confidence among investors. We are “tremendously” undervalued at this point, should already be $1 to $2 price [much less .45/.55] compared to competition in the market.
2. Hopefully when we actually see the full line of data it will stand up to the hype Glynn and others [Edith Perez, Keith Knutson] are quietly portraying, which will finally give credibility to stock.
3. Within 6 months Phase 11 should have started, in which case the whole game will have changed, charts will not be able to predict what investors will do at that time.
4. There are many, many investors still on the sidelines waiting for this massive inflection point, resistance may dry up immediately.
5. Resistance dries up in stocks all the time on news much smaller than a company entering into Phase 11 with multiple indications...with billion dollar valuations.
6. Our large institutional investors may up their participation in the stock, making purchases in the actual market as support to get a Nasdaq listing.
7. Float is very low, limited selling, and possibility of funds, institutions buying small positions for clients will not be out of the question, moving stock steadily to the upside.
8. Nasdaq listing will be a major point, for if the technology is that good into Phase 11, stock could very easily hit $2 to $4 this year, funding will already be in place anywhere after $1.50 any indication of a Nasdaq listing may rally stock.
9. If a buyout is going to happen it will happen sooner than later [18/24 months] possible. Their technology may be very sought after valuation in the $5 to $10 area very possible.
10. Glynn mentioned that they have applications for grant funding that may come into effect sometime this year, once again a real possibility if data is as good as predicted.
Simply laying out very possible scenarios that may occur in TPIV over the next six months, Tapimmune’s simple vaccine injection not having to manipulate cells outside the body then reintroduce them will be the most cost effective in the industry. A great selling point to the FDA on the Fast Track, and IND status.
A Stock such a Tap immune doesn’t come along every day, just saying be careful on watching charts as changes may come rapidly and frequently.
Hope any of this helps.
Blu
Not to mention...fast track, orphan status possible IND and minimum $ 34 million financing already in place $1.50 or less.
Hurdles have already been addressed and overcome, really you don't think this is going over $1.50 by year end as 2 maybe 3 trials will have progressed into phase 11.
Not to mention that our technology is synergistic to majority of Big Pharma that may be further along in trials, and much more cost effective that is a very big unadressed point so far. Would not only compliment, but would increase other technologies.
Edith Perez Keith Knutson one of the best in the world, our technology is going to be applicable to diseases as time plays out.
They have not even ventured into the infectious disease aspect of the technology, may spin that off to shareholders down the road.
Nothing but positives, bashers have very little to work with.
Blu
123tom Glynn is very, very conservative and reluctant to bring out press at this time because they are very sensitive to the FDA at this point. They are not going to jeopardize years of hard work to front run the upcoming clinical news.
Two weeks away is ASCO and many questions should be answered by then, they are not in control of releasing news at this time the Mayo still is.
To all..it is a very sensitive time for them everything must be done in a timely manner and adhere to strict protocols.
Buy on weakness... but keep core position, no question this has the potential to be a monster.
Look on the website they have put up the bit with Edith Perez, look how exited she is...they've got the goods.
Blu
Has anyone had the chance to see the abstract I found, in my last post going to be done by Keith?
Thanks JJ for that DD, I found that Keith Knutson is putting on an poster board presentation, here are the details I have found so far.
Go to ASCO site
Go to search the program.
Clear all boxes of check marks.
then
Check Track Breast Cancer.
go to
Cross Cutting Themes
check on clinical trials
go down to search click on
Sessions comes up
go down to Sat May 30 8AM to 11:30AM
click on
Breast Cancer HEr2/ER
Presentations comes up
scroll down to ABSTRACT #587 Keith Knutson
it seems like it is blank at the moment but sure looks like he will be giving a presentation looks to me like another ABSTRACT.
Maybe someone here can figure it out, either way good that he will be speaking. Let me know if anyone finds it maybe we can find out the body of work he is presenting before ASCO
Blu
You're welcome 123, considering the consolidation in the Bio Tech space in the past two years and that TPIV's Technologies would be synergistic to any Big Pharma.
A successful Phase 1 and progression into Phase 11 would make TPIV a very tempting acquisition and since the science has been validated since 1993, and has attracted such world renowned immunologist as Edith Perez, and our lead Keith Knutson. Both who seem to be very excited about the progression, the science is safe, very cost effective compared to all others that may be further along. TPIV's technology will be complimentary to even the giants like JUNO, KITE, IMMUNOGEN and many others. Mayo seems to be doing well in getting the grants, we are well placed with them at the moment, although there political process has a lot to be desired.
Likewise the Big investors and partners [Lasko/Bonfiglio] that have positioned their bets lead me too believe they may have the pull and partnership to make that happen.
Don't believe that they are looking to go into Phase 111.
Blu
123tom in regards to your question, I do believe that anywhere from 25 and up is an excellent entry point. I have seen/been through a lot with TPIV, most I must admit has been tough, only the savviest of investors have survived.
There are many catalyst's in TPIV's near term future that should propel it from what has been regarded as simply a great prospect to a remarkably viable company.
I am a proponent of dollar cost averaging, "if" the fundamentals of a company do not change to the down side. No one finds the bottom yet many strive to do so and miss out on the big picture.
The worst is over [being a going concern] having said that investing is not for the faint of heart DD is "KING".
Tapimmune's technology started with Wilfred Jefferies back at UBC many years ago, and it is just now that the technology finally seems to be getting the credit it deserves.
Any investing should be based on one's own degree of risk, in TPIV one's core should be .30 and down, may it retract from here have seen it many times before. But they are very close to releasing Phase 1 data and there will be no back from there, buy your core position then add on weakness. I personally being here for years now believe this is it, I bought TPIV for the technology and they are a tremendous buyout candidate, many Big Pharma are looking for new technologies and companies patents as many expired in 2014.
If a buyout were to happen it would most likely occur in 18 to 24 months $10 would not be out of the question by any means, even with all warrants exercised 80 to 100 million shares out at $10, $800 mill. We have already seen that scenario twice in the Bio sector [actually a billion plus]
I am a Warren Buffet disciple so I tend to look for very undervalued companies with little debt and low floats with great technologies or products and buy/average and hold. But like to be ahead of the herd like I did with TPIV.
Great to see you all have the same sentiment this is a "MONSTER"
GLTA Am here investing every day will help if I can.
Welcome JBEM777, salgovernale69, ash111,123TOM and other Newcomers
I am a long term investor in TPIV, unfortunately went through the 1/100 reverse but was left with 10,000 shares and was able to unload into the $7 run got out at $5.17 so made back most of the money most lost. For all that went through it and lost if you have bought more you are/will be handsomely rewarded [Patience]
It is nice to see so many educated and positive newcomers, I know management quite well over the past 5 years, I was involved in a round of the financing, but more of a Warren Buffet disciple.
Long term holder on this one, because it is going to be a monster, be careful not to miss out on the big moves. Have been acquiring from .18 to .22 on top of financing.
Don't worry about Dakota he has been a basher here for a long time, on Oct 8/2014 he made some inappropriate comments and I responded in kind. he then accused me of trying to attack him physically and I have not responded until today.
Simply ignore him.
I am well versed in most area's of Tapimmune so if I may be of any help please let me know, and I will try to answer. I have been investing for over 30 years, mainly finding severely undervalued companies. GLTA
Been a loyal [intelligent] investor for many years...
enough said, not your business but pre and post up north of mentioned amount.
Holdings [shares] north of 100K!
Actually...up about $37,000,
plus my more than adequate position!
Dakota: Just allows "us with money" to buy more, at very depressed levels.
Once again see you at year end and start of 2015, you clearly do not understand the science, you a confirmed "basher" that allowed me hopefully others to get another bunch of cheap shares.
Sitting on quite a nice position, thanks to all the sceptics and idiots.
Shorts are playing with fire as one of these times soon...there will be no place to cover without padding us longs pockets further.
Thanks again!
Blu
GREAT ARTICLE: Tappimmune/Tekmira
What's Next: Investors Place Ebola Pandemic Stock Bets
One strong candidate which has seen a quiet increase in activity/volume lately is tiny TapImmune Inc. (OTCQB:TPIV - News).
Like Tekmira, TapImmune offers investors an infectious disease side bet while serving up a main course of “new frontier” cutting-edge science-- in this case, a pipeline of multiple cancer vaccines showing superior results in human clinical trials. Those results strongly support progression to Phase ll and a very realistic shot at Orphan Drug Designation for multiple drug candidates in the short term.
TapImmune, despite having multi-billion dollar product potential in Breast and Ovarian Cancer- two separate large market indications with clearly unsatisfied medical needs- has not been able to catch the attention of most investors. In fact, the Seattle based microcap has seen its share prices hit after a recent corporate re-structure and a financing deal which has armed them with new resources.
That has not dissuaded at least some speculators from quietly picking up shares in growing volumes at currently discounted levels for what some believe to be a 5x to 10x opportunity. In fact, volume has been rising on the recent positive clinical data and since rumors began to spread that the firm’s PolyStart™ technology may be getting attention from bigger firms and government agencies- this after successful preclinical work at Mayo Clinic showed the platform can boost vaccine productivity FOUR fold, which becomes particularly relevant as the Ebola threat continues to spread more aggressively.
PolyStart™, which was primarily, developed “in-house” by Bob Florkiewicz, PhD as a way of boosting the effectiveness of TapImmune’s existing Her2Neu and Ovarian Cancer vaccines, but it is such a versatile ‘plug and play’ technology, its potential for treating infectious diseases including influenza, H1N1, Dengue, and yes, Ebola cannot be ignored or overemphasized. Even as the platform is likely being prepared for an Ebola application, serious investors in the company have given kudos to the firm for not trying to jumping on the Ebola band wagon. Still, as this threat gains momentum and global panic grows, we believe the technology could play a major role in its containment and eradication given the right collaboration and partners- some of which are rumored to be circling.
Those who understand PolyStart’s™ mechanism of action, say that it can increase the effectiveness of just about any vaccine and perhaps provide a platform countermeasure to bioterrorism. In short, the PolyStart™ expression vector is a significant advance in vaccine technologies which may not be ignored much longer.
Image: https://d1ty0e8cxefhfl.cloudfront.net/contributor/ME-Garza/user_content/ckimages/orig_TPIVInfectious.jpg
It’s worth noting that Florkiewicz, who serves as Senior Director of Molecular Biology & Virology at TapImmune,was at ID Biomedical when GlaxoSmithKlineagreed to buy the Canadian vaccine developer for C$1.7 billion.
The way we see it, whether inferring from company presentations or street rumors about PolyStart™ as an infectious disease play out in the weeks ahead or not, the firm has made clear to investors a series of important pipeline milestones and catalysts which could certainly spur more buying and interest. Most recently, during their presentation at the at the 16th Annual Rodman & Renshaw Global Investment Conference, management also told investors that it plans to seek an up listing to the Nasdaq as soon as possible. That hints at, and would require, a significantly higher share price.
Finally, when one considers that TapImmune has only 19M outstanding shares with roughly 8M in the float and that it trades at prices significantly lower than those of other players in the immunotherapy space by 5 or 10X, downside risk at these levels is certainly minimized.
Sleepy:
The wind is blowing...obviously you have "not' done your "DD" otherwise you would understand the science.
Any Biotech is a minimum 7 year process, their platform and technology is a relatively unproven concept therefore the skepticism.
Tapimmune is a long term project and if you are in for a big, quick return not the stock for you...or if you can not handle risk.
The company is very well positioned to break through this time,
1. Very low float.
2. Enough capital to see them through Phase 1 on Two, multi billion dollar markets, second round of financing if successful will be much higher and take them into Phase 3 clinical.
3.Ground breaking Technology on many fronts, is a great takeover target buy Big Pharma as it gains greater acceptance.
Do more DD on the Science/Management and success to this point past is the past...many successful Biotech's have the same track record.
Hope too see you still here 6 month's from now, story may well be very different.
GLTA Blu
Salix: So what is your total position now?
Blu
Salix: How many shares did you own pre split [ie 1 million,2?
I million would translate into only 10,000, 2 20,000 and so on.
You talk of "free" shares often...did you short the stock from 7,5?
And would be interested how many shares you own now total?
You are right buying opportunity soon, when whoever is shorting the stock runs out, time is very close but they seem to have little support but some buyers/covering shorts at these levels.
People should be playing TPIV as a long term buy at this point, looks like it is going to be 3 months to Phase 2 on both trials.
And NASDAQ listing only when clinical trials are completed.
Thanks for your input, have been an investor for better part of 40 years, am well positioned in TPIV. Know the stock very well have been in for better part of 6 years.
Will await a reply
BluMarlin1960
Dakota
We have listened to your relentless bashing of Tapimmune for some time now.
It is beyond my comprehension why you would bash a company that is pursuing a path that may save thousands or millions of lives and the pain and suffering that cancer inflicts.
Other than some petty monetary gain...
My mother succumbed to ovarian cancer after a long and arduous battle. I wish no ill harm to you or yours, but if God forbids any one you love and cherish is diagnosed with any form of cancer and dies in the process...at that very moment that you/they are informed that they have a short undetermined time to live...
...maybe you will remember this note and think of me I am sure that at that moment you will finally understand why their research is so very, very important.
God Bless, but even God won't save them/you to "Cancer"
Dakota you are so wrong...
There will be very little dilution. Financing will be coming very soon, very very soon look for something in the range of $2.50 - $3
by the reaction of the news looks like it may already have been done yesterday or this week on what will be perceived as outstanding news. Will carry the company well into 2015 at that point TPIV will be listed on a major exchange and strong contender for a large Pharma to buy them out. They have many avenues that they may pursue.
That will raise $15 million plus on approx. 22 million shares outstanding, a very tight restructuring. Management, after dropping the ball with the previous thieves have redeemed themselves.
The fact that the "Mayo Clinic" is moving forward with this new trial shows that the first trial has been extremely positive. TPIV is just on the tip of the iceberg, their only downfall at this moment is being on the OTC Bulletin Board. It will take approx. 3 months with a $4 plus stock print to meet the requirement of NASDAQ, or NYSE.
Their pipeline will be very deep and because of the low float once they achieve a higher listing TPIV may well be one of the most sought after stocks in 2014.
Your comment shows your complete lack of DD, that myself and others have done over the past 4 years, our belief has finally been vindicated with a nice paycheck.
The fact that the new trial has already been fully subscribed is outstanding, for there are many markers for exclusion in HER2/nue, dilution will be minimal...watch and see.
Their management is strong, well versed in Oncology and clearly showing that they are capable of steering TPIV forward, any short positions we will gladly welcome because this truly is a great story. We actually need the dilution because the float is way to tight, don't like the large swings in price need the dilution to settle it down.
Need to get off the OTC as soon as possible.
To all the holders like me that have persevered over the past 4 years "or longer" look forward to analyzing information and data with you in 2014 and beyond.
STRONG BUY [ Already have a large position]
Once again that is not correct, they will/have great interest from a variety of funding sources, the small dilution is needed to give liquidity to the stock...short term downside "maybe"!
because of the small float, but on the flipside any selling/shorting only propels it back to these levels and beyond.
Your posts show your lack of overall market acuity, as well as your lack od DD...good time to short now...go ahead.
Dakota: Better to keep your mouth shut and be perceived as an idiot, than to open it and remove all doubt.
Too late for you!
DAKOTA...our first "Basher" obviously without any knowledge.
Congrats that you are our first board "Basher" unfortunately you are very wrong, as I have been in the stock for 5 years, look for a small financing in the $2.50 to $3 range maybe 5 to 8 million shares raising 15 to 20 million.
Our debt is gone, less than $500,000, this first small financing which is going to take us into 2015 will only dilute the stock to the tune of 22 to 25 million outstanding, with the float being very tight.
Everyone who participated in the debt restructuring have Tapimmune's best interest at heart, expect little selling.
News that will be forthcoming will propel the stock much, higher, I personally will be looking for shorts like you to try to drive stock down because along the course those propellants will help our stock tremendously.
Do your DD this is one of the tightest restructuring that I have seen, with what is going to play out to be maybe one of the greatest stories in a long time.
Bring your friends, short at will... we actually welcome all comers.
They have the Technology, they are in the space, multi billion market. Will go as a stand alone, or there will be many Big Pharma's looking to acquire our Technology. All data has been peer reviewed, this first news yesterday is just the tip of the iceberg.
They will have no problem up listing to either NASDAQ, or NYSE, vaccine technology is best platform by far, interest behind the scenes is already gaining ground.
1. Financing small dilution, but needed to make more liquidity.
2. Up listing to larger exchange.
3. Multi billion dollar markets, with most comprehensive platform in many areas.
4. Great takeover target, but with their proprietary Technology will garner a big premium.
5. All data has been published in peer reviewed journals.
GLTA I believe that there already are many Big Pharma's, that have been watching our technology, but have not been able to participate because the OTC listing and the mess the stock was in.
Everything has changed and once the overall market gets wind of what is going on and the above mentioned catalysts Tapimmune will determine it's own destiny.
I am well invested and already profitable at this point, the game has not even started.
Buy on an weakness, going into the financing it may be the only chance to get your position in the just under 3 range, but because the float is so tight don't expect much, and it will only propel our positions higher...I will thank you in advance for that participation on your behalf..
Bashers will be battling for the scraps those of us that are aware of the story either have our positions or will be buying before additional news and market awareness fully addresses Tapimmune's potential.
DAKOTA: Look forward to proving you, the first basher of our stock wrong, good luck see you in 6 months.
STRONG BUY
Bio7mm and Big stogie.
The news in monumental, what you need to understand in that it needs a few weeks to be disseminated into the market, we are on the OTC a market with virtually no rules. Mutual funds and others large institutions still cannot buy for clients at this price.
The financing is what needs to be put in place, my understanding is that they are thinking in the $2.50 to 3 range, that will give them approx. 15 mill cash, MM will try in the next few weeks to knock this down to this area.
But with the low float and no sellers because debt financing is most likely tied up, so the financing will help with liquidity much needed at this point.
Buy on any weakness as in a couple of months this will be much higher, financing and NASDAQ or NYSE listing is also in the works.
Need to put out 2 or 3 press updates, next 2 or 3 weeks will flush out most sellers, than the news will propel us higher.
Just understand that many individual investors do not know about us, as info gets spread to the marketplace we will pop, and look for Big Pharmas who are most likely following us to step in on any new news.
GLTA
TPIVD...HER2/neu Data out, covers 84% of population most comprehensive platform to date.
What did I just post?
Great synopsis Master S, here's my take...
Let me add, as I monitored all last week, it looked like most of the trading was cashing out board lots less than 100 shares, the buying looked like they were trying to fulfill the 400 shareholder minimum guideline to meet NASDAQ, and NYSE guidelines.
It is apparent that they did a great job in the debt restructuring and are focused on making their vaccine platform [Tap technology] world class .
1: They have many directions to go. Not only does their pipeline encompass approx 84% of the HER2neu population but may be extended beyond just Breast and Ovarian Cancer this may very well make them a highly regarded takeover candidate. At a premium much higher than where we stand today, their vaccines also seem to be complimentary to many other medical applications.
2. Although their trials may not be as advanced as some other companies, with the adequate funding in place they will be able to fast track their technology and make up that ground.
3. Partner with a well selected pharmaceutical Co.
4. Spin off their Bio-defence arm to another company in that space, or spin it off to us shareholders.
5. Strong Patent protection and focused on making it stronger.
It truly is an inspiring platform and seems to be the "only" and "most comprehensive" to date. I have been in the company for approx, 5 years and the future looks very bright if their technology is as sound as initial data implies.
Wilfred Jefferies who was the one who started it all back in the late 90's was confident that the TAP technology was ground breaking even then, we are very close to seeing if his work was sound. If it is this stock will be one of the most sought after in the world.
I have traded for many years and this is one of the best restructurings I have seen, with the perfect technology, in the right space at the right time that I can remember. I see very few flaws that the likes of Seeking Alpha and other cronies will be able to discredit, as most if not all research has been documented in Peer Reviewed Journals.
It appears that we may in the perfect storm with Tapimmune, the next six months will tell, safety and efficacy in the Phase 1 trial seem to have been met.
Tapimmune needs to bring Phase 1 clinical update as soon as possible, I am sure that they are working diligently to advance all fronts.
Look for press sometime next week, and financing in the near future, when that is put in place it makes Tapimmune a much sought after entity. I expect that they will get their listing on either NASDAQ or NYSE in 2014 maybe within months.
GLTA,existing shareholders like myself who is a big buyer at these levels, and welcome all new shareholders. With a financing of 5 to 6 million shares any where over $2.50 but more likely over $3 we raise approx $15 million,enough to fund them through 2014 and beyond, with only approx 22 to 25 million outstanding shares and a very tight float that will jump with any substantial buying. Next financing will be done at much higher levels, float is tied to the restructuring so may be a hold on any selling for 3 to 6 months. Which means that trying to wait for the share price to back of substantially may mean missing out on the first big move which in my opinion is coming soon.
Tapimmune seems like one of the rare R/S stories that will succeed, shorties not only have very little stock to accumulate, but run the risk of getting slaughtered when the real data becomes available.
Look forward to Tapimmune's future and hearing other's take on their technology who may be better versed on the medical side of the story.
GLTA: Strong Buy
QuietTim: You must go to Nasdaq website type in TPIV go to SEC filings and you will just how many shares and warrants have been issued last year [approx. 100 million more with the warrants] and mostly at 0.01 cent. So you are incorrect when the share price was .20 financing was there only block, now it is the a combination of lack of financing and severe dilution. The massive R/S is the only way to move forward, if you are educated investor and believe in DD then you would have seen this scenario playing out much sooner. I believed in the technology and still do are most of us going to lose money...yes...but the company itself moving forward will be much stronger, I will wait to see Phase1 and how market reacts to R/S [shorts] then assess and buy more on weakness. GLTA
QuietTim: Respect your opinion, but the facts are that they need to do the R/S as soon as possible to keep the company afloat. As TPIV sits now the have been using stock dilution to finance every aspect of their daily operation. Still owe about 4 to 5 million, Mayo still needs balance to be paid, must raise at least another 5 million. The only reason that this was not done last year was because of the ongoing lawsuit [which by the way they lost $250,000] appeal is in process. R/S will allow the company to have a very solid structure in which to go after financing. No one will look at them at 0.01/0.02 I made all aware of the impending massive split month's ago [check my posts] we all have been hurt by the events that have occurred. Phase1 news most likely just around the corner [within 3 months] why would any company bring out that news with the terrible structure of the company. In order to move forward with the Phase1 press they must be restructured completely, thus the R/S will be fairly soon once again nothing is written in stone. It is not good news for any of us long term holders of TPIV.
QuietTim: Reverse split is going to be in the very near term, I would say 30 days at the outside, my take through my DD most likely sooner. We will just have to wait and see, but that is the most likely scenario at this moment.
MASTERSALIX: Believe have outstanding right now 145 million,it would be 145 million outstanding lets just say 150 million divided by 100 1.5 million plus the 6,250,000 = 7,750,000 million outstanding after 100:1 my take as SEC indicates? May be other stock we don't know lets say 10 million after R/S.
That is a very tight float and will mostly be held by insiders, if they come out with great news Post R/S should hold share price up against any short sellers, who usually hit a stock after R/S, financing also should be no problem...if Phase 1 gets completed and results are positive. Getting there but still a way to go!
There's millions of shares around 0.01 and 0.2/0.25 they are trying to consolidate their debt at 0.01. This is not going anywhere for a while, and they may not be able to secure the financing in the end. I have tried to make it clear how dire their position is at the moment, the people on this board seem to think that it is going to go through the ask, they are just going to throw out stock at 0.01/0.0125 area. The massive volume with TPIV is a big problem, not anyone buying, "debt consolidation" there are 10's of millions of shares to go yet, they are trying to stay afloat till they can get through Phase 1. But still owe the Mayo Clinic, have 5 million debt and need to raise another 4 to 5 million in a dilutive financing no one wants to get involved until Phase 1 is completed, BK is a real reality at the moment. Once again I am a long, love the Technology but cannot be a buyer at this time, own quite a lot of stock but will not even average my position here.
I do not like the reality any more than any one else on this board, Glynn has put all of us long term investors at considerable risk to lose everything. Am I pissed yes but this is where we are at the moment.
GLTA
If you believe in the "Company" than you have not done your DD, now if you believe in the Technology than you and I are in agreement. I am only trying to give you fair warning that there are still many make or break issues to be ironed out be prudent. They do not own the tech yet, and a split or worse is coming.
Once again Long but am not a buyer here "yet"
GLTA